AZN Stock Recent News
AZN LATEST HEADLINES
Pascal Soriot, CEO of British pharmaceutical giant AstraZeneca, discusses the company's $2.5 billion investment in a new China research and development center.
Pascal Soriot, CEO, AstraZeneca discusses the company's $2.5 billion investment in its new China research and development centre.
SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands , March 21, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in immunology and oncology, today announced a global strategic collaboration with AstraZeneca to discover and develop next-generation multi-specific antibodies for immunology, oncology and beyond.
British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing, China. Outside the Macclesfield factory of AstraZeneca.
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year.
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) has completed two major projects for AstraZeneca PLC (LSE:AZN), expanding the use of its Parsortix liquid biopsy system to support clinical trials in prostate and multiple cancer types. The system isolates cancer cells from a simple blood sample, providing a non-invasive way to monitor how a patient's disease is responding to treatment.
The latest trading day saw Astrazeneca (AZN) settling at $76.32, representing a -0.97% change from its previous close.
HAMBURG, Germany--(BUSINESS WIRE)--The collaboration aims to assess the transformative potential of AI in digital pathology, with a specific focus on accelerating primary breast cancer diagnosis. Breast cancer remains one of the leading causes of cancer-related deaths in women worldwide. Early and accurate diagnosis is essential for significantly improving clinical outcomes and patient survival rates. However, this process is often hindered by a limited pathology workforce and time-consuming ca.
The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based on ADRIATIC study data.
AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or immune-mediated diseases.